CNMD logo

CONMED Corporation Stock Price

NYSE:CNMD Community·US$1.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

CNMD Share Price Performance

US$0
-47.84 (-100.00%)
US$39.60
Fair Value
US$0
-47.84 (-100.00%)
Price US$0

CNMD Community Narratives

·
Fair Value US$39.6 9.7% overvalued intrinsic discount

Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$36.17 20.1% overvalued intrinsic discount

Rising Costs And Supply Risks Will Impair Future Performance

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$40 8.6% overvalued intrinsic discount

Global Aging And Minimally Invasive Trends Will Empower Future Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$36.17
20.1% overvalued intrinsic discount
Revenue
3.63% p.a.
Profit Margin
11.53%
Future PE
7.13x
Price in 2029
US$45.27
US$39.6
9.7% overvalued intrinsic discount
Revenue
3.24% p.a.
Profit Margin
12.44%
Future PE
7.4x
Price in 2029
US$50.1
US$40
8.6% overvalued intrinsic discount
Revenue
4.15% p.a.
Profit Margin
11.12%
Future PE
8.13x
Price in 2029
US$50.52

Trending Discussion

No trending discussion available.

Updated Narratives

CNMD logo

CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026

Fair Value: US$36.17 20.1% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CNMD logo

CNMD: Gastro Exit And Buybacks Will Support Future Profit Margin Upside

Fair Value: US$39.6 9.7% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CNMD logo

CNMD: Refocused Surgical Portfolio And Buybacks Will Test Medtech Reset

Fair Value: US$40 8.6% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

3 Risks
3 Rewards

CONMED Corporation Key Details

US$1.4b

Revenue

US$627.6m

Cost of Revenue

US$742.9m

Gross Profit

US$688.0m

Other Expenses

US$54.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 29, 2026
1.82
54.20%
4.00%
84.5%
View Full Analysis

About CNMD

Founded
1970
Employees
3900
CEO
Patrick Beyer
WebsiteView website
www.conmed.com

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Recent CNMD News & Updates

Narrative Update Jul 16

CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026

CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.

Recent updates

No updates